CHCWM – Cancer & Hematology Centers of West Michigan

Abbvie (VERONA)

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.

AstraZeneca D8227C00001 (ACERTA ESCALADE)

Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.

CA031002 (Bristol-Myers Squibb)

A Phase 1/2 First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors

University of Chicago (COBRA)

  A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) PI: Dr. Brinker Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion  

Celgene Connect MDS/AML

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry Primary Investigator: Dr. Erin Pettijohn For more information on this trial, read its profile on clinicaltrials.gov here.

MMY3021 (AURIGA)

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant Principal Investigator: Dr. Erin Pettijohn For more information on this trial, read its profile on clinicaltrials.gov here.

Seattle Genetics (ECHELON-3)

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Principal Investigator: Dr. Erin Pettijohn For more information on this trial, read its profile on clinicaltrials.gov here.